|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
64,210,000 |
Market
Cap: |
N/A |
Last
Volume: |
141 |
Avg
Vol: |
1,513,129 |
52
Week Range: |
$0.000001 - $0.238 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
410,196 |
425,190 |
Total Sell Value |
$0 |
$0 |
$28,714 |
$38,646 |
Total People Sold |
0 |
0 |
1 |
2 |
Total Sell Transactions |
0 |
0 |
1 |
2 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Berkowitz Jeffrey |
Director |
|
2016-06-17 |
4 |
A |
$1.52 |
$39,999 |
D/D |
26,315 |
30,384 |
|
- |
|
Bertrand William C Jr |
General CounselOfficer |
|
2015-10-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,500 |
|
- |
|
Berkowitz Jeffrey |
Director |
|
2015-09-01 |
4 |
A |
$8.60 |
$34,993 |
D/D |
4,069 |
4,069 |
|
- |
|
Evnin Anthony B |
Director |
|
2015-09-01 |
4 |
A |
$8.60 |
$17,492 |
D/D |
2,034 |
93,934 |
|
- |
|
Lander Eric S |
Director |
|
2015-09-01 |
4 |
A |
$8.60 |
$17,492 |
D/D |
2,034 |
73,741 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-06-25 |
4 |
AS |
$10.93 |
$54,650 |
D/D |
(5,000) |
359,432 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2015-06-15 |
4 |
S |
$10.97 |
$51,965 |
D/D |
(4,737) |
868 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-05-27 |
4 |
AS |
$12.81 |
$128,100 |
D/D |
(10,000) |
364,432 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-05-14 |
4 |
AS |
$12.18 |
$121,800 |
D/D |
(10,000) |
374,432 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2015-04-30 |
4 |
OE |
$2.04 |
$9,663 |
D/D |
4,737 |
5,605 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-03-16 |
4 |
AS |
$16.00 |
$320,000 |
D/D |
(20,000) |
384,432 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-03-05 |
4 |
AS |
$16.50 |
$412,500 |
D/D |
(25,000) |
404,432 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-01-29 |
4/A |
AS |
$14.83 |
$296,536 |
D/D |
(20,000) |
429,432 |
|
- |
|
Perkins Adelene Q |
President & CEO |
|
2015-01-29 |
4 |
AS |
$14.83 |
$296,536 |
D/D |
(20,000) |
427,535 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-12-15 |
4 |
AS |
$16.32 |
$77,294 |
D/D |
(4,737) |
0 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-12-15 |
4 |
OE |
$2.04 |
$9,663 |
D/D |
4,737 |
4,737 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-11-26 |
4 |
AS |
$15.00 |
$71,040 |
D/D |
(4,736) |
0 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-11-26 |
4 |
OE |
$2.04 |
$9,661 |
D/D |
4,736 |
4,736 |
|
- |
|
Evnin Anthony B |
Director |
|
2014-10-03 |
4 |
OE |
$11.85 |
$307,765 |
D/D |
24,500 |
91,900 |
|
- |
|
Evnin Anthony B |
Director |
|
2014-09-30 |
4 |
S |
$13.56 |
$1,525,229 |
I/I |
(112,451) |
0 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-09-03 |
4 |
AS |
$15.39 |
$145,774 |
D/D |
(9,472) |
0 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-09-03 |
4 |
OE |
$2.04 |
$19,323 |
D/D |
9,472 |
9,472 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-07-01 |
4 |
AS |
$12.87 |
$11,313 |
D/D |
(879) |
0 |
|
- |
|
Palombella Vito J. |
Chief Scientific Officer |
|
2014-06-30 |
4 |
A |
$10.83 |
$9,520 |
D/D |
879 |
879 |
|
- |
|
Selby Norman C |
Director |
|
2014-03-06 |
4 |
OE |
$8.87 |
$22,175 |
D/D |
2,500 |
10,000 |
|
- |
|
227 Records found
|
|
Page 4 of 10 |
|
|